Table 3.
Summary of clinical trials using iCasp9 CAR-T cells.
| Target | Cancer Types | NCT Number |
|---|---|---|
| GD2 | DIPG and DMG | NCT04196413 |
| Relapsed/refractory neuroblastoma |
NCT01822652 NCT03721068 NCT03373097 |
|
| Refractory/metastatic GD2-positive sarcoma or neuroblastoma |
NCT01953900 NCT02107963 |
|
| Solid cancers | NCT02992210 | |
| CD19 | Relapsed/refractory ALL |
NCT03016377 NCT03594162 |
| Relapsed/refractory B-cell lymphoma |
NCT03696784 NCT03579927 |
|
| CD19 & CD22 | Relapsed/refractory B-cell lymphoma | NCT03098355 |
| CD30 | Relapsed/refractory CD30-positive lymphomas | NCT02274584 |
| Mesothelin | Solid cancers | NCT02414269 |
| Advanced breast cancer | NCT02792114 |